APONTIS PHARMA AG (APPH.DE) Fundamental Analysis & Valuation

FRA:APPH • DE000A3CMGM5

Current stock price

11 EUR
0 (0%)
Last:

This APPH.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. APPH.DE Profitability Analysis

1.1 Basic Checks

  • APPH had positive earnings in the past year.
  • APPH had a negative operating cash flow in the past year.
  • In multiple years APPH reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: APPH reported negative operating cash flow in multiple years.
APPH.DE Yearly Net Income VS EBIT VS OCF VS FCFAPPH.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

  • APPH's Return On Assets of 1.70% is on the low side compared to the rest of the industry. APPH is outperformed by 60.71% of its industry peers.
  • The Return On Equity of APPH (2.34%) is worse than 60.71% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 2.01%, APPH is doing worse than 64.29% of the companies in the same industry.
Industry RankSector Rank
ROA 1.7%
ROE 2.34%
ROIC 2.01%
ROA(3y)-4.37%
ROA(5y)-3.69%
ROE(3y)-9.26%
ROE(5y)-12.74%
ROIC(3y)N/A
ROIC(5y)N/A
APPH.DE Yearly ROA, ROE, ROICAPPH.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

  • APPH has a Profit Margin (1.55%) which is in line with its industry peers.
  • The Operating Margin of APPH (2.60%) is worse than 64.29% of its industry peers.
  • APPH's Operating Margin has declined in the last couple of years.
  • With a Gross Margin value of 57.16%, APPH is not doing good in the industry: 67.86% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of APPH has declined.
Industry RankSector Rank
OM 2.6%
PM (TTM) 1.55%
GM 57.16%
OM growth 3Y-32.83%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
APPH.DE Yearly Profit, Operating, Gross MarginsAPPH.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. APPH.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so APPH is destroying value.
  • Compared to 1 year ago, APPH has about the same amount of shares outstanding.
  • APPH has less shares outstanding than it did 5 years ago.
  • APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APPH.DE Yearly Shares OutstandingAPPH.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
APPH.DE Yearly Total Debt VS Total AssetsAPPH.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • APPH has an Altman-Z score of 6.01. This indicates that APPH is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 6.01, APPH belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
  • APPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.01
ROIC/WACC0.28
WACC7.19%
APPH.DE Yearly LT Debt VS Equity VS FCFAPPH.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

  • A Current Ratio of 6.82 indicates that APPH has no problem at all paying its short term obligations.
  • APPH has a better Current ratio (6.82) than 98.21% of its industry peers.
  • APPH has a Quick Ratio of 4.86. This indicates that APPH is financially healthy and has no problem in meeting its short term obligations.
  • APPH has a Quick ratio of 4.86. This is amongst the best in the industry. APPH outperforms 98.21% of its industry peers.
Industry RankSector Rank
Current Ratio 6.82
Quick Ratio 4.86
APPH.DE Yearly Current Assets VS Current LiabilitesAPPH.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. APPH.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 106.98% over the past year.
  • Looking at the last year, APPH shows a very strong growth in Revenue. The Revenue has grown by 31.12%.
  • Measured over the past years, APPH shows a small growth in Revenue. The Revenue has been growing by 3.89% on average per year.
EPS 1Y (TTM)106.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%

3.2 Future

  • APPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 128.83% yearly.
  • Based on estimates for the next years, APPH will show a quite strong growth in Revenue. The Revenue will grow by 15.31% on average per year.
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APPH.DE Yearly Revenue VS EstimatesAPPH.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
APPH.DE Yearly EPS VS EstimatesAPPH.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. APPH.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 122.22, APPH can be considered very expensive at the moment.
  • 67.86% of the companies in the same industry are cheaper than APPH, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 24.88. APPH is valued rather expensively when compared to this.
  • A Price/Forward Earnings ratio of 11.20 indicates a reasonable valuation of APPH.
  • Based on the Price/Forward Earnings ratio, APPH is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, APPH is valued a bit cheaper.
Industry RankSector Rank
PE 122.22
Fwd PE 11.2
APPH.DE Price Earnings VS Forward Price EarningsAPPH.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, APPH is valued a bit more expensive than the industry average as 69.64% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.66
APPH.DE Per share dataAPPH.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as APPH's earnings are expected to grow with 128.83% in the coming years.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y194.54%
EPS Next 3Y128.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APPH.DE Dividend Analysis

5.1 Amount

  • No dividends for APPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

APPH.DE Fundamentals: All Metrics, Ratios and Statistics

APONTIS PHARMA AG

FRA:APPH (11/14/2025, 7:00:00 PM)

11

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-26
Earnings (Next)N/A
Inst Owners38.49%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap93.50M
Revenue(TTM)48.47M
Net Income(TTM)750.00K
Analysts82.86
Price Target13.77 (25.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)35%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)71.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.13%
Valuation
Industry RankSector Rank
PE 122.22
Fwd PE 11.2
P/S 1.93
P/FCF N/A
P/OCF N/A
P/B 2.92
P/tB 7.19
EV/EBITDA 30.66
EPS(TTM)0.09
EY0.82%
EPS(NY)0.98
Fwd EY8.93%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS5.7
BVpS3.76
TBVpS1.53
PEG (NY)0.31
PEG (5Y)N/A
Graham Number2.76
Profitability
Industry RankSector Rank
ROA 1.7%
ROE 2.34%
ROCE 3.08%
ROIC 2.01%
ROICexc 2.01%
ROICexgc 3.75%
OM 2.6%
PM (TTM) 1.55%
GM 57.16%
FCFM N/A
ROA(3y)-4.37%
ROA(5y)-3.69%
ROE(3y)-9.26%
ROE(5y)-12.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.09%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.79%
ROICexc growth 5YN/A
OM growth 3Y-32.83%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.69%
GM growth 5Y-4.61%
F-Score5
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 214.53%
Cap/Sales 7.92%
Interest Coverage 9.69
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.82
Quick Ratio 4.86
Altman-Z 6.01
F-Score5
WACC7.19%
ROIC/WACC0.28
Cap/Depr(3y)153.48%
Cap/Depr(5y)119.91%
Cap/Sales(3y)6.51%
Cap/Sales(5y)4.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y393.69%
EPS Next 2Y194.54%
EPS Next 3Y128.83%
EPS Next 5YN/A
Revenue 1Y (TTM)31.12%
Revenue growth 3Y-1.8%
Revenue growth 5Y3.89%
Sales Q2Q%14.55%
Revenue Next Year21.53%
Revenue Next 2Y20.18%
Revenue Next 3Y18.69%
Revenue Next 5Y15.31%
EBIT growth 1Y113.36%
EBIT growth 3Y-34.04%
EBIT growth 5YN/A
EBIT Next Year419.89%
EBIT Next 3Y131.3%
EBIT Next 5YN/A
FCF growth 1Y16.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.68%
OCF growth 3YN/A
OCF growth 5YN/A

APONTIS PHARMA AG / APPH.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for APONTIS PHARMA AG?

ChartMill assigns a fundamental rating of 5 / 10 to APPH.DE.


Can you provide the valuation status for APONTIS PHARMA AG?

ChartMill assigns a valuation rating of 4 / 10 to APONTIS PHARMA AG (APPH.DE). This can be considered as Fairly Valued.


What is the profitability of APPH stock?

APONTIS PHARMA AG (APPH.DE) has a profitability rating of 1 / 10.


What is the expected EPS growth for APONTIS PHARMA AG (APPH.DE) stock?

The Earnings per Share (EPS) of APONTIS PHARMA AG (APPH.DE) is expected to grow by 393.69% in the next year.